58333-75-8

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-Methoxyphenyl)piperidine is used as a therapeutic agent for the treatment of neurodegenerative disorders and depression. Its application is based on its ability to modulate the central nervous system and act as a selective NMDA receptor antagonist, which may help alleviate symptoms associated with these conditions.
Used in Research and Development:
In the field of research and development, 4-(2-Methoxyphenyl)piperidine is used as a chemical probe to study the role of NMDA receptors in various neurological processes and disorders. Its psychoactive properties also make it a subject of interest for understanding the mechanisms of action of dissociative anesthetics and hallucinogens.
Used in Drug Abuse Prevention and Education:
Due to its potential for misuse and abuse, 4-(2-Methoxyphenyl)piperidine is also used in the development of strategies for drug abuse prevention and education. Understanding its effects and mechanisms of action can help in the creation of awareness programs and policies to mitigate the risks associated with its use.

InChI:InChI=1/C12H17NO/c1-14-12-5-3-2-4-11(12)10-6-8-13-9-7-10/h2-5,10,13H,6-9H2,1H3

Upstream product

• 100192-56-1 3-(2-Methoxy-phenyl)-glutarsaeureimid 
• 113411-59-9 1-benzyl-4-(2-methoxyphenyl)-1,2,3,6-tetrahydro-pyridine 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 194669-41-5 1-t-Butoxycarbonyl-4-(2-methoxyphenyl)-1,2,3,6-tetrahydropyridine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 16750-63-3 2-methoxyphenylmagnesium bromide 
• 154422-95-4 1,2,3,6-tetrahydro-4-(2-methoxyphenyl)pyridine 
• 201609-28-1 1-t-Butoxycarbonyl-4-hydroxy-4-(2-methoxyphenyl)piperidine 
• 135-02-4 ortho-anisaldehyde 
• 105338-50-9 3-(2-methoxyphenyl)pentanedioic acid 
• 5720-06-9 2-Methoxyphenylboronic acid 
• 201609-29-2 1-t-Butoxycarbonyl-4-(2-methoxyphenyl)piperidine 

Downstream Products

• 474710-94-6 6-bromo-4-[4-(2-methoxyphenyl)piperidin-1-yl]quinazoline 
• 58333-76-9 [4-(2-methoxy-phenyl)-piperidin-1-yl]-acetonitrile 
• 1376334-48-3 8-chloro-3-(cyclopropylmethyl)-7-[4-(2-methoxyphenyl)-1-piperidinyl]-1,2,4-triazolo[4,3-a]pyridine 
• 1552303-62-4 C₂₇H₃₆BrNO₃ 
• 1616294-18-8 2-cyclopropyl-6,7-dimethoxy-4-[4-(2-methoxy-phenyl)-piperidin-1-yl]-quinazoline 
• 1032061-65-6 C₁₂H₁₆N₂O₃ 
• 1032061-63-4 2-(1-methyl-[4]piperidyl)-phenol; hydrobromide 
• 1064701-77-4 {3-[4-(4-chloro-phenyl)-tetrahydro-pyran-4-yl]-[1,2,4]oxadiazol-5-ylmethyl}-{2-[4-(2-methoxy-phenyl)-piperidin-1-yl]-ethyl}-amine, hydrochloride 
• 1064700-79-3 {3-[1-(4-chloro-phenyl)-cyclobutyl]-[1,2,4]oxadiazol-5-ylmethyl}-{2-[4-(2-methoxy-phenyl)-piperidin-1-yl]-ethyl}-amine hydrochloride 
• 1064702-30-2 {3-[4-(4-chloro-phenyl)-tetrahydro-pyran-4-yl]-[1,2,4]oxadiazol-5-ylmethyl}-{2-[4-(2-methoxy-phenyl)-piperidin-1-yl]-ethyl}-amine 
• 1064701-90-1 {3-[1-(4-chloro-phenyl)-cyclobutyl]-[1,2,4]oxadiazol-5-ylmethyl}-{2-[4-(2-methoxy-phenyl)-piperidin-1-yl]-ethyl}-amine 
• 58333-77-0 2-[4-(2-methoxy-phenyl)-piperidin-1-yl]-ethylamine 

Relevant academic research and scientific papers

2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS

Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

20-HETE FORMATION INHIBITORS

This disclosure provides novel heterocyclic compounds and methods for inhibiting the enzyme CYP4. Further disclosed methods include: a method of inhibiting the biosynthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) in a subject in need thereof and a method of producing neuroprotection and decreased brain damage by preventing cerebral microvascular blood flow impairment and anti-oxidant mechanisms in a subject experiencing or having experienced an ischemic event.

Successful reduction of off-target hERG toxicity by structural modification of a T-type calcium channel blocker

To obtain an optimized T-type calcium channel blocker with reduced off-target hERG toxicity, we modified the structure of the original compound by introducing a zwitterion and reducing the basicity of the nitrogen. Among the structurally modified compound

SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1

Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

Synthesis, evaluation, and radiolabeling of new potent positive allosteric modulators of the metabotropic glutamate receptor 2 as potential tracers for positron emission tomography imaging

The synthesis and in vitro and in vivo evaluation of a new series of 7-(phenylpiperidinyl)-1,2,4-triazolo[4,3-a]pyridines, which were conveniently radiolabeled with carbon-11, as potential positron emission tomography (PET) radiotracers for in vivo imagin

Serotonin 5-HT1A and dopamin D2 receptor ligands

The present invention relates to a novel series of 4-phenylpiperazines, 4-phenylpiperidines and 4-phenyl-1,2,3,6-tetrahydropyridines compounds of general formula (I) wherein A is alkylene, alkenylene, alkynylene, and C3-7cycloalkylene; R1is a C3-10alkyl, alkenyl, or alkynyl group, cycloalk(en)yl, cycloalk(en)yl-alk(en/yn)yl, trifluoromethylsulfonyl, or alkylsulfonyl, R2-R5are optional substituents; R9and R10are hydrogen, alkyl or together form an ethylene or propylene bridge; W is O or S; V is O, S, CR6R7, or NR8wherein R6, R7, and R8are hydrogen or alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, optionally substituted arylalkyl or aryl, or R6and R7constitute a 3-7 membered spiro ring; Z is —(CH2)m—, m being 2 or 3 or Z is —CH═CH—; X is N, C or CH; show effects on central serotonin 5-HT1Aand dopamine D2receptors. Thus the novel compounds are useful in the treatment of certain psychic and neurologic disorders, in particular psychosis.

2,2-DIPHENYLBUTANAMIDE DERIVATIVES AND MEDICINES CONTAINING THE SAME

2,2-Diphenylbutanamide derivatives represented by the following formula (1): [wherein A represents -(CH2)n- (n is 1 or 2) or a methine (CH) group; when A is -CH2-, B represents a methine group or a nitrogen atom, with A and B forming a single bond; when A is -(CH2)2-, B represents a nitrogen atom, with A and B forming a single bond; when A is a methine group, B represents a quaternary carbon atom, with A and B forming a double bond; each of R1 and R2, which are identical to or different from each other, represents a hydrogen atom, a lower alkyl group, or a cycloalkyl group, or R1 and R2 may form a heterocyclic ring together with the adjacent nitrogen atom; and Ar represents an optionally substituted phenyl group, bicyclic aromatic ring, monocyclic heterocyclic ring, bicyclic heterocyclic ring, or fluorene group]; or salts of the derivatives. The derivatives or salts thereof exhibit excellent μ-opioid agonist activity and analgesic activity against neuropathic pain, and are useful as medicines such as peripheral analgesic drugs and neuropathic pain relieving drugs.

Tetrahydrobenzindole compounds

A compound of formula (I) for use in the treatment or prevention of mental diseases A is N, CH, C having a double bond or CR5; each of B and Z is independently N, CH or CR1, with the proviso that A is N when B and/or Z is N; R1, R2, R3, R4and R5and n are as defined in the specification.

Serine derived NK1 antagonists 2: A pharmacophore model for arylsulfonamide binding

Modifications to the spirocyclic aryl sulfonamide portion of serine derived NK1 antagonists allow a partial pharmacophore model to be developed.

σ Ligands with subnanomolar affinity and preference for the σ2 binding site. 1. 3-(ω-Aminoalkyl)-1H-indoles

A series of 4-(1H-indol-3-yl)-1-butyl-substituted 4-phenylpiperidines, 4- phenyl-1,2,3,6-terrahydropyridines, and 4-phenylpiperazines was synthesized. The phenyl group was optionally substituted with 4-fluoro or 2-methoxy substituents. High affinity for both σ1 and σ1 binding sites was achieved with these compounds. Additionally, these compounds had relatively high affinity for serotonin 5-HT(1A) and 5-HT(2A), dopamine D2, and adrenergic α1 receptors. Introduction of a 4-fluorophenyl substituent at the indole nitrogen atom rendered very selective σ2 ligands with subnanomolar affinity for the σ2 binding site. The prototype of such a compound was 1-(4- fluorophenyl)-3-[4-[4-(4-fluorophenyl)-1-piperidinyl]-1-butyl]-1H-indole, 11a (code no. Lu 29-253). This compound had the following binding affinities: IC50 (σ1) = 16 nM, IC50 (σ2) = 0.27 riM, IC50 (5-HT(1A)) = 22 000 nM, IC50 (5-HT(2A)) = 270 nM, IC50 (D2) = 4200 nM, IC50 (α1) = 220nM. Spiro-joining of the phenyl and the piperidine rings into a spiro[isobenzofuran-1(3H),4'-piperidinel ring system resulted in even more selective compounds. Variations of the 1-substituent at the indole and of the chain length of the alkylene spacer group were studied. The optimal compound was the spiro analogue of compound 11a. This compound is 1'-14-[1(4- fluorophenyl)-1H-indol-3-yl]-1-butyl]spiro[isobenzofuran-1(3H),4'- piperidine], 14f (code no. Lu 28-179), with the binding affinities: IC50 (σ1) = 17 nM, IC50 (σ2) = 0.12 nM, IC50 (5-HT(1A)) = 21 000 nM, IC50 (5-HT(2A)) = 2000 nM, IC50 (D2) = 800 nM, IC50 (α1) = 330 nM. However, the most selective σ2 versus σ1 ligand was the tropane derivative 1-(4-fluorophenyl)-3-[4-[3-(4-fluorophenyl)-8- azabicyclo[3.2.1]oct-2-en-8-yl]-1-butyl]-1H-indole, 15a. This compound had the following binding affinities: IC50 (σ1) = 1200 nM, IC50 (σ2) = 2.5 nM. Potent anxiolytic activity in the black/white box exploration test in rats was found with the two most prominent σ2 ligands Lu 29-253 and Lu 28- 179. Good penetration into the CNS was documented both after subcutaneous and peroral administration of Lu 28-179 by ex vivo binding studies. Long duration of action was demonstrated both in ex vivo binding (T(1/2) ~ 20 h) and in the black/white box exploration test.